Understand the source comparison
Sermorelin Protocol Comparison: Daily vs Intermittent Dosing
Daily subcutaneous (200–500 mcg) Once nightly, 30–60 min before bed IGF-1 elevation measurable at 14–21 days; 20–40% increase from baseline by week 4 Improved sleep quality at 10–14 days; recovery enhancement at 4–6 weeks; body composition changes at 8–12 week
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Daily subcutaneous (200–500 mcg)
- Once nightly, 30–60 min before bed
- IGF-1 elevation measurable at 14–21 days; 20–40% increase from baseline by week 4
- Improved sleep quality at 10–14 days; recovery enhancement at 4–6 weeks; body composition changes at 8–12 weeks
- Requires consistent nightly injection; timing relative to sleep onset is critical; reconstituted peptide stable 28 days refrigerated
- Most effective for sustained metabolic outcomes; aligns with natural GH pulse architecture
- 5-days-on / 2-days-off cycling
- 5 consecutive nights per week
- IGF-1 elevation slightly delayed; measurable at 21–28 days
- Physical outcomes delayed by 2–3 weeks vs daily protocol
- Weekend breaks reduce injection burden; may prevent receptor downregulation over extended use
- Useful for long-term therapy (6+ months); slightly slower initial response but maintains sensitivity
- Intermittent (3x weekly)
- Monday/Wednesday/Friday or similar
- IGF-1 response inconsistent; peaks and troughs prevent sustained elevation
- Physical outcomes unreliable; some users report no measurable benefit
- Lower cost; less frequent reconstitution needed
- Not recommended for therapeutic goals; insufficient frequency to maintain elevated IGF-1 baseline
- Daily dosing is the gold standard for sermorelin therapy because growth hormone secretion operates on a circadian rhythm. The peptide works by amplifying the body's natural GH pulse, not creating one from scratch. Intermittent dosing disrupts that rhythm and produces inconsistent IGF-1 elevation, which is why clinical trials universally use daily administration. The 5-on/2-off protocol is a reasonable compromise for extended therapy beyond 6 months, where receptor sensitivity maintenance becomes a concern. But it delays initial results compared to uninterrupted daily dosing.